Novel hCD3e Mouse Models for Preclinical Pharmacology Study of Therapeutic Bispecific Antibody

Novel hCD3e Mouse Models for Preclinical Pharmacology Study of Therapeutic Bispecific Antibody

Author: Jie Xiang, Yanan Li, Yuelei Shen, Yanan Guo

AACR Annual Meeting 2019 # 1469CD3e is one of four subunits of the CD3 co-receptor, which plays an important role in the immune response, associating with the T cell receptor (TCR) to couple antigen recognition to intracellular signal transduction, leading to T cell activation. However, in many cases, we cannot directly evaluate the antibody candidates in mice because the monoclonal antibodies specific to human CD3 cannot cross-react to mouse endogenous CD3. In order to overcome the current model limitation, we have generated CD3e-extracellular domain KI mice for anti-human CD3e bispecific antibody in vivo efficacy evaluation. We have characterized our B-hCD3e mice with the following features:

  1. Mouse CD3e+ cells were detected in the wildtype C57BL/6 mice, while human CD3e+ cells were only detected in the homozygous B-hCD3e mice.
  2. T cell development was normal in B-hCD3e homozygous mice.
  3. T cell subtypes in the spleen, thymus, lymph nodes, and PBMC in B-hCD3e mice were similar and comparable to that in wildtype C57BL/6 mice.
  4. Normal in vitro T cell proliferation and cytokine production were found in anti-hCD3e antibody treated humanized B-hCD3e mice
  5. Mouse anti-PD-1 antibody can significantly repress the growth of MC38 tumor cells engrafted on B-hCD3e mice, suggesting that T cells in B-hCD3e mice are functionally normal
  6. Treatment of B-hCD3e mice with anti-human CD3e antibody OKT leads to T cell depletion, resulting in more aggressive tumor growth.

Share:

Please fill out the form below to request a download of this poster